SCHEMBL2230558

SCHEMBL2230558

CCCCCCCCCCC[C@@H](OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OCCCCC(=O)OC)C(C)CCCCCC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.57
NR5A2 O00482 1/20 0.57
NR5A1 Q13285 1/20 0.57
RECQL P46063 1/20 0.56
MAPT P10636 3/20 0.55
MAPK1 P28482 5/20 0.54
MEN1 O00255 3/20 0.54
GMNN O75496 3/20 0.54
LMNA P02545 3/20 0.54
BLM P54132 3/20 0.54
KMT2A Q03164 3/20 0.54
NPSR1 Q6W5P4 3/20 0.54
TP53 P04637 2/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2D6 P10635 2/20 0.54
CYP2C9 P11712 2/20 0.54
ALOX15 P16050 2/20 0.54
NFKB1 P19838 2/20 0.54
CYP2C19 P33261 2/20 0.54
HIF1A Q16665 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15153607 0.91 RECQL (0.62) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL2237805 0.91 RECQL (0.62) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL2232177 0.91 RECQL (0.62) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL1962710 0.90 SMN1; SMN2 (0.60) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL20143294 0.87 RECQL (0.72) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL2230910 0.87 RECQL (0.72) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL2231964 0.87 RECQL (0.72) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL2231689 0.87 RECQL (0.72) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL2233048 0.85 ALDH1A1 (0.71) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL2230639 0.84 RECQL (0.67) SMN1; SMN2NR5A2NR5A1RECQLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206206-B2 Oxidized lipid compounds and uses thereof VASCULAR BIOGENICS LTD. (IL) 2015-12-08 US disclosed
EP-2826369-A2 Oxidized lipid compounds and uses thereof Vascular Biogenics Ltd. (IL) 2015-01-21 EP disclosed
EP-2826370-A2 Oxidized lipid compounds and uses thereof Vascular Biogenics Ltd. (IL) 2015-01-21 EP disclosed
EP-2348866-B1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD (IL) 2015-01-07 EP disclosed
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof VASCULAR BIOGENICS LTD. (IL) 2013-08-08 US disclosed
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof LPO, GPX4, ALOX15B SMN1; SMN2 4440/4885NR5A2 2001/4885NR5A1 1208/4885
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF LPO, GPX4, ALOX15B SMN1; SMN2 4440/4885NR5A2 2001/4885NR5A1 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.